Treatment recommendations for metastatic colorectal cancer

被引:20
作者
Aranda, Enrique [1 ]
Abad, Albert [2 ]
Carrato, Alfredo [3 ]
Cervantes, Andres [4 ]
Garcia-Foncillas, Jesus [5 ]
Garcia Alfonso, Pilar [6 ]
Garcia Carbonero, Rocio [7 ]
Gomez Espana, Auxiliadora [1 ]
Tabernero, Josep M. [8 ]
Diaz-Rubio, Eduardo [9 ]
机构
[1] Hosp Univ Reina Sofia, Dept Med Oncol, ES-14004 Cordoba, Spain
[2] Hosp Germans Trias & Pujol ICO, Barcelona, Spain
[3] Hosp Ramon & Cajal, E-28034 Madrid, Spain
[4] Hosp Clin, Valencia, Spain
[5] Clin Navarra, Navarra, Spain
[6] Hosp Gen Gregorio Maranon, Madrid, Spain
[7] Hosp Univ Virgen Rocio, Inst Biomed Sevilla IBIS, Seville, Spain
[8] Hosp Valle De Hebron, Barcelona, Spain
[9] Hosp Clin San Carlos, Madrid, Spain
关键词
Metastatic colorectal cancer; Chemotherapy; PERIOPERATIVE INTRAPERITONEAL CHEMOTHERAPY; CETUXIMAB PLUS IRINOTECAN; PHASE-III TRIAL; CIRCULATING TUMOR-CELLS; HIGH-DOSE LEUCOVORIN; CONTINUOUS-INFUSION FLUOROURACIL; THYMIDYLATE SYNTHASE EXPRESSION; COMPLETE CYTOREDUCTIVE SURGERY; RESECTABLE LIVER METASTASES; SPANISH COOPERATIVE GROUP;
D O I
10.1007/s12094-011-0636-7
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Metastatic colorectal cancer (CRC) represents an important health problem in which several biological predictive and prognostic factors have been identified, including clinical features and molecular markers that might influence the response to treatment. Actually, certain prognostic factors are considered key elements, along with disease extent, for deciding the therapeutic approach. However, a distinction between resectable/potentially resectable and unresectable patients must be made in order to establish an adequate therapeutic strategy. Different drugs and chemotherapy regimens are currently available, and their administration depends on patient characteristics, disease-related factors and the treatment objective. Moreover, special situations such as peritoneal carcinomatosis and local treatment of CRC in the setting of metastatic disease should be considered when deciding the most appropriate treatment strategy. This article reviews all the previously mentioned issues involved in the management of metastatic CRC and suggests some general recommendations for its treatment.
引用
收藏
页码:162 / 178
页数:17
相关论文
共 192 条
[61]   Utility of 18F-FDG positron emission tomography scanning on selection of patients for resection of hepatic colorectal metastases [J].
Fong, YM ;
Saldinger, PF ;
Akhurst, T ;
Macapinlac, H ;
Yeung, H ;
Finn, RD ;
Cohen, A ;
Kemeny, N ;
Blumgart, LH ;
Larson, SM .
AMERICAN JOURNAL OF SURGERY, 1999, 178 (04) :282-287
[62]  
Fuchs CS, 2007, J CLIN ONCOL, V25, P4779, DOI 10.1200/JCO.2007.11.3357
[63]  
GAYOWSKI TJ, 1994, SURGERY, V116, P703
[64]   Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery [J].
Giacchetti, S ;
Itzhaki, M ;
Gruia, G ;
Adam, R ;
Zidani, R ;
Kunstlinger, F ;
Brienza, S ;
Alafaci, E ;
Bertheault-Cvitkovic, F ;
Jasmin, C ;
Reynes, M ;
Bismuth, H ;
Misset, JL ;
Lévi, F .
ANNALS OF ONCOLOGY, 1999, 10 (06) :663-669
[65]   Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200 [J].
Giantonio, Bruce J. ;
Catalano, Paul J. ;
Meropol, Neal J. ;
O'Dwyer, Peter J. ;
Mitchell, Edith P. ;
Alberts, Steven R. ;
Schwartz, Michael A. ;
Benson, Al B., III .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (12) :1539-1544
[66]   Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: A multi-institutional study [J].
Glehen, O ;
Kwiatkowski, F ;
Sugarbaker, PH ;
Elias, D ;
Levine, EA ;
De Simone, M ;
Barone, R ;
Yonemura, Y ;
Cavaliere, F ;
Quenet, F ;
Gutman, M ;
Tentes, AAK ;
Lorimier, G ;
Bernard, JL ;
Bereder, JM ;
Porcheron, J ;
Gomez-Portilla, A ;
Shen, P ;
Deraco, M ;
Rat, P ;
Gilly, FN .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) :3284-3292
[67]  
Goldberg RM, 2007, J CLIN ONCOL, V25
[68]   The continuum of care: A paradigm for the management of metastatic colorectal cancer [J].
Goldberg, Richard M. ;
Rothenberg, Mace L. ;
Van Cutsem, Eric ;
Benson, Al B., III ;
Blanke, Charles D. ;
Diasio, Robert B. ;
Grothey, Axel ;
Lenz, Heinz-Josef ;
Meropol, Neal J. ;
Ramanathan, Ramesh K. ;
Becerra, Carlos H. Roberto ;
Wickham, Rita ;
Armstrong, Delma ;
Viele, Carol .
ONCOLOGIST, 2007, 12 (01) :38-50
[69]   A Randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer [J].
Goldberg, RM ;
Sargent, DJ ;
Morton, RF ;
Fuchs, CS ;
Ramanathan, RK ;
Williamson, SK ;
Findlay, BP ;
Pitot, HC ;
Alberts, SR .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (01) :23-30
[70]   Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment [J].
Grothey, A ;
Sargent, D ;
Goldberg, RM ;
Schmoll, HJ .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (07) :1209-1214